Article Information
History
- June 26, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Tian Yao, MD*,1,3,
- Xiaohong Zhang, MM*,4,5,
- Shengcai Mu, MM*,4,5,
- Yana Guo, BM2,3,
- Xiuyang Xu, BM2,3,
- Junfeng Huo, MM4,5,
- Zhiyun Wei, MM4,5,
- Ling Liu, MM4,5,
- Xiaoqing Li, MM4,5,
- Hong Li, MM4,5,
- Rongqin Xing, BM6,
- Yongliang Feng, MD†,2,3,‡,
- Jing Chen, MM†,4,5,‡,
- Lizhong Feng, MM4,5,†,‡ and
- Prof Suping Wang, MD2,3,†,‡
- 1First Hospital/First Clinical Medical College of Shanxi Medical University, Taiyuan, China
- 2School of Public Health, Shanxi Medical University, Taiyuan, China
- 3Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, China
- 4Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
- 5Shanxi Provincial Key Laboratory for major infectious disease response
- 6Outpatient Department of Shanxi Aviation Industry Group Co. LTD
- ↵‡Correspondence to: Suping Wang, School of Public Health, Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, 030001, China, supingwang{at}sxmu.edu.cn, Lizhong Feng, Shanxi Provincial Center for Disease Control and Prevention, Shanxi Provincial Key Laboratory for major infectious disease response, Taiyuan, 030012, China, 1508717672{at}qq.com, Jing Chen, Shanxi Provincial Center for Disease Control and Prevention, Shanxi Provincial Key Laboratory for major infectious disease response, Taiyuan, 030012, China, 524210737{at}qq.com, Yongliang Feng, School of Public Health, Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, 030001, China, yongliang.feng{at}sxmu.edu.cn
↵* Contributed equally
Posted June 26, 2022.
Long-term immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population Secondary Study Based on a Randomized Clinical Trial
